Clinical trials: Cancer-Related Syndrome
Acute Myeloid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
This phase I trial studies the side effects and immune response to DEC-205/NY-ESO-1 fusion protein CDX-1401 and decitabine in patients with myelodysplastic syndrome or acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT01834248
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute
Neurofibromatosis
Quality of Friendships in Children With Neurofibromatosis
The aim of this study is to determine if children with a higher disease severity have lower quality friendships than children who are less severely affected and children who are unaffected.
- Trial name
- NCT00508235
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 61 people
- Sponsor
- M.D. Anderson Cancer Center
Hematologic Malignancy, GvHD
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell…
- Conditions
- Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic
- Trial name
- NCT06462365
- Testing
- TRX103
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Tr1X, Inc.
Breast Cancer
Pecs II Block and PaB Could be an Alternative in Breast Surgery
The association between ultrasound-guided Pecs II block and parasternal block can represent a valid alternative in the management of acute and postoperative pain syndrome after quadrantectomy with or without axillary dissection.
- Trial name
- NCT02865265
- Testing
- Pecs II and parasternal blocks
- Volunteers
- 180 people
- Sponsor
- Emiliano Petrucci
Sarcoma, Kaposi, HIV Infections
Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients
The purpose of this study is to see if it is safe and effective to use IM862 to treat Kaposi's sarcoma (KS) in AIDS patients.
- Trial name
- NCT00002445
- Testing
- IM862
- Where
- 42 sites in United States, Australia and 2 more
- Volunteers
- 200 people
- Sponsor
- Cytran
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer
The primary objective of this study is to compare safety and efficacy of a haploidentical T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell replete HSCT with post-transplant administration…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- HATCY (NCT02999854)
- Testing
- ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor
- Where
- 42 sites in United States, Belgium and 11 more
- Volunteers
- 63 people
- Sponsor
- Kiadis Pharma
Neurofibromatosis 1, Plexiform Neurofibroma
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
A study to evaluate the efficacy of FCN-159 in adult patients with symptomatic, inoperable neurofibromatosis type 1-related plexiform neurofibromas.
- Conditions
- Neurofibromatosis 1, Plexiform Neurofibroma, NF1
- Trial name
- NCT05913037
- Testing
- Test group (Group A): FCN-159 8 mg, orally, once daily;
- Where
- 15 sites in China
- Volunteers
- 167 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy
Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes
This phase II trial studies the effect of adding pomalidomide to usual chemotherapy treatment (daunorubicin and cytarabine liposome) in treating patients with newly diagnosed acute leukemia with myelodysplastic syndrome-related…
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT04802161
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine
- Where
- 11 sites in United States
- Volunteers
- 49 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
This phase I trial studies the best dose of total body irradiation when given with cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) or idarubicin, fludarabine, cytarabine and filgrastim (FLAG-Ida) chemotherapy…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia
- Trial name
- NCT04375631
- Testing
- Cladribine, Cyclophosphamide, Cyclosporine
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Fred Hutchinson Cancer Center
HIV Infections
A Study of Tumor Necrosis Factor and Human Interferon-gamma in Patients With AIDS Related Complex
To study the tolerance and toxicity of the combination of tumor necrosis factor (TNF) and interferon gamma (IFN-G) or as single agent TNF or IFN-G in HIV infected patients.
- Trial name
- NCT00001004
- Testing
- Tumor Necrosis Factor, Interferon gamma-1b
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
This phase I clinical trial is studying the side effects and the best dose of lenalidomide after donor bone marrow transplant in treating patients with high-risk hematologic cancer.
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
- Trial name
- NCT01254578
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Immune-Related Adverse Events, Lupus Erythematosus, Systemic
Interferon Signature in Anti-CTLA-4 and Anti-PD-1/PD-L1-Treated Cancer Patients Compared With Systemic Autoimmune Disease Patients
This study aims to identify a way to predict the side effects that some people with cancer experience when receiving immunotherapy.
- Conditions
- Immune-Related Adverse Events, Lupus Erythematosus, Systemic, Sjogren Syndrome, Systemic Sclerosis (SSc)
- Trial name
- INTER-AUTENTIC (NCT07249060)
- Testing
- Immune Checkpoint Inhibitors
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Hospital Universitario Araba
Hand-Foot Syndrome, Breast Cancer
Ice Plant Intensive Cream for the Prevention of Hand-Foot Syndrome in Breast Cancer: Pilot Randomized Controlled Trial
The present pilot study investigates the feasibility of a prospective larger confirmatory study on the efficacy of Dr. Hauschka Med Ice Plant Intensive Cream for the prevention of hand-foot syndrome in patients with breast…
- Trial name
- WIn-HFS (NCT05755646)
- Testing
- Ice Plant Intensive Cream plus Standard Care, Standard Care
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University Hospital Tuebingen
Leukemia, Myelodysplastic Syndromes
S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid Leukemia
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells.
- Trial name
- NCT00005866
- Testing
- busulfan, cyclophosphamide, cyclosporine
- Where
- 66 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- SWOG Cancer Research Network
HIV Infections
A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3
Original design: The study's purpose is to compare the effects of zidovudine (AZT) alone to the combination of AZT and acyclovir (ACV) to determine if AZT/ACV is associated with a lower death rate and fewer AIDS related…
- Trial name
- NCT00000712
- Testing
- Zidovudine, Acyclovir
- Where
- 8 sites in United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Neurofibromatosis 1
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
Background: NF1 is a genetic disease that causes tumors called atypical neurofibromas. These tumors, which arise from nerves, can cause serious medical problems. The only treatment is surgery.
- Trial name
- NCT04750928
- Testing
- Abemaciclib
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Neurofibromatosis 1, Neurofibromatosis 2
The NF Registry Sponsored by the Children's Tumor Foundation
The NF Registry is a database of patient-reported symptoms, treatments, and experiences with their neurofibromatosis disease. It is a contact registry to relay clinical trial opportunities to targeted patient subgroups, and to…
- Conditions
- Neurofibromatosis 1, Neurofibromatosis 2, Schwannomatosis, NF2-related Schwannomatosis
- Trial name
- NCT01885767
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- The Children's Tumor Foundation
NF1 Mutation, Neurofibroma Plexiform
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
The main purpose of this clinical trial is to test PAS-004 in people with at least one symptomatic plexiform neurofibroma due to Neurofibromatosis Type 1 (NF1).
- Conditions
- NF1 Mutation, Neurofibroma Plexiform, Neurofibroma, Plexiform, Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs)
- Trial name
- NCT06961565
- Testing
- PAS-004 Tablets, PAS-004 Capsule
- Where
- 5 sites in United States, Australia and 1 more
- Volunteers
- 56 people
- Sponsor
- Pasithea Therapeutics Corp.
HIV Infections, Lymphoma, AIDS-Related
A Pilot Study of Non-Hodgkin's Lymphoma: Chemotherapy and Blood Levels of Organochlorines
Non-Hodgkin's lymphoma (NHL) is the third most rapidly increasing cancer in the United States. HIV-related NHL is responsible for some of the increase since the early 1980s.
- Conditions
- HIV Infections, Lymphoma, AIDS-Related, Lymphoma, Non-Hodgkin
- Trial name
- NCT00001571
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma
Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail
Hepatocellular carcinoma (HCC) is a common fatal malignant tumor, although with the popularity of health examination, most patients were diagnosed as HCC in advanced stages so far.
- Trial name
- NCT02961998
- Testing
- Celecoxib, Sorafenib
- Volunteers
- 116 people
- Sponsor
- Sun Yat-sen University